β-Amyloid (1-17) is a peptide of β-Amyloid, stabilizes the fibres and plays a role in Aβ fibre formation.
β-Amyloid 1-17 is a synthetic peptide fragment derived from the N-terminal region of the full-length amyloid beta (Aβ) protein, a molecule of central importance in neurodegenerative research. Comprising the first seventeen amino acids of the Aβ sequence, this peptide retains key biochemical motifs relevant to the aggregation, binding, and cellular interaction properties characteristic of amyloid proteins. Its truncated structure makes it an invaluable tool for dissecting the molecular determinants of amyloidogenesis, as well as for studying the physiological and pathological roles of amyloid fragments in cellular and molecular neuroscience. Researchers leverage β-Amyloid 1-17 to explore fundamental questions in protein aggregation, membrane interactions, and the mechanisms underlying amyloid precursor protein (APP) processing.
Aggregation studies: As a defined N-terminal fragment, β-Amyloid 1-17 is frequently employed in in vitro aggregation assays to assess the minimal sequence requirements for amyloid fibril formation. Its use allows scientists to compare the aggregation kinetics and morphological features of shorter Aβ fragments with those of longer peptides, providing insight into the sequence determinants that drive oligomerization and fibrillization. Such studies are pivotal for understanding the molecular basis of amyloid plaque formation and for identifying sequence-specific inhibitors or modulators of aggregation.
Membrane interaction research: Due to its amphipathic nature, β-Amyloid 1-17 serves as a model peptide for investigating Aβ interactions with lipid bilayers and biological membranes. It is utilized in biophysical and biochemical assays to elucidate how the N-terminal region of amyloid beta associates with membrane components, influences membrane integrity, and potentially contributes to cytotoxicity. These experiments help clarify the mechanisms by which amyloid peptides disrupt cellular membranes, a process implicated in neurodegenerative pathologies.
Proteolytic processing analysis: The peptide is a valuable substrate for studying the enzymatic cleavage patterns of amyloid precursor protein by secretases and other proteases. By monitoring the generation or degradation of β-Amyloid 1-17 in enzymatic assays, researchers can map cleavage sites, assess protease specificity, and evaluate the effects of mutations or inhibitors. This application supports the broader investigation of APP metabolism and the regulation of amyloidogenic and non-amyloidogenic processing pathways.
Antibody epitope mapping: β-Amyloid 1-17 is widely used in immunochemical assays to map antibody binding sites and characterize the specificity of monoclonal or polyclonal antibodies targeting the Aβ N-terminus. Its defined sequence enables precise determination of epitope recognition, which is essential for the development and validation of immunoassays, diagnostic reagents, and research antibodies. This application is particularly important for distinguishing between different Aβ species in complex biological samples.
Analytical and detection assay development: The peptide fragment is incorporated into a variety of analytical platforms, including ELISA, western blotting, and mass spectrometry-based assays, as a standard or calibration control. Its use facilitates the quantification and detection of amyloid beta species in experimental samples, supporting both basic research and the evaluation of potential biomarkers. By providing a reliable reference, β-Amyloid 1-17 enhances the accuracy and reproducibility of analytical methods focused on amyloid biology.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More